Plenvu

ApprovedSmall molecule

JJohannes Gutenberg University Mainz

Plenvu is one of 35 small molecule programs targeting Colorectal Cancer. It is currently in Approved.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Colorectal CancerActive, not recruiting

Colorectal CancerApproved

Active, not recruiting

Competition

Competitive Landscape

949 competitors in Colorectal Cancer

#DrugCompanyPhaseTrials

Plenvu

JJohannes Gutenberg University Mainz

Approved

1 2

Eylea

Regeneron

Preclinical

5 3

PORTRAZZA

Emend IV

Xylocaine

1 6

Gas-X

PPortuguese Oncology Institute, Coimbra

Preclinical

1 7

Ultiva

PPfizer's Upjohn has merged with Mylan to form Viatris Inc.

Preclinical

1 8

Versed

CConrado Roberto Hoffmann Filho

Preclinical

1 9

Bridion

CCidara Therapeutics Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)

Preclinical

1 10

Feraheme

AAzurity Pharmaceuticals

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q1 2027

Phase 3Recruiting

Colonoscopy

NCT07218523

Clinical

Trials by Indication[1]

Colonoscopy3 trials

A Study to Investigate Bowel Cleansing With PLENVU® Compared to Sodium Picosulfate in Participants Aged 1 to < 18 Years of Age in Preparation for Colonoscopy

Recruiting·NNorgine·Phase 3·NCT07218523·212 enrolled

Comparison of Two Preparations for the Study of the Colon Through Colonoscopy

Completed·UUnidade Local de Saúde do Alto Ave, EPE··NCT04497935·613 enrolled

A Trial to Compare Efficacy and Tolerability of Plenvu® and Picoprep® as Cleansing Agents Before Colonoscopy

Recruiting·—·Phase 4·NCT05436054·400 enrolled

Bowel Preparation2 trials

Effect of Low-volume (1L) vs Intermediate-volume (2L) Bowel Preparation on Cost-effectiveness and Quality of Life

Completed·RRadboud University Medical Center·N/A·NCT05242562·509 enrolled

QR Code for Endoscopic Bowel Preparation

Unknown status·JJohannes Gutenberg University Mainz··NCT04456231·404 enrolled

Colorectal Cancer1 trial

Two Low Volume Regimens for Colorectal Cancer Screening Colonoscopy

Completed·HHospital Clinic of Barcelona·Phase 4·NCT04297423·1,002 enrolled

Effectiveness1 trial

Effectiveness of PLENVU in the General Screening Population and Patients With IBD

Unknown status·JJohannes Gutenberg University Mainz··NCT04457934·290 enrolled

Sources

References

[1]
ClinicalTrials.gov — 7 trial records for Plenvu. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Plenvu compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Plenvu. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Johannes Gutenberg University Mainz company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Approved[1]
Company: JJohannes Gutenberg University Mainz

Plenvu

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q1 2027

Trials by Indication[1]

Colonoscopy3 trials

Bowel Preparation2 trials

Colorectal Cancer1 trial

Effectiveness1 trial

References

Drug Info

Quick Facts

Related News